Adverse event profile of CGRP monoclonal antibodies: findings from the FDA adverse event reporting database

CONCLUSION: We identified numerous shared underlying signals (overlapping signals) for CGRP-mAbs as suspected drugs in multiple systems and organs. The unlabeled common signals may indicate potential safety issues. In addition, the underlying safety signals varied among the four CGRP-mAbs, particularly in the cardiovascular system, and further studies are needed to confirm these associations and the potential clinical implications.PMID:37720989 | DOI:10.1080/14740338.2023.2250720

Source: Expert Opinion on Drug Safety - September 18, 2023 Category: Drugs & Pharmacology Authors: Qi Wang Jingfang Liu Hao Sun YongFei Dong WeiLiang Tan Zaixiang Tang YiGuo Jiang Source Type: research